Prognostic Value of E-Cadherin and β-Catenin in Triple-Negative Breast Cancer

Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer

(2016) Jingdan Qiu et al.   Journal of Cancer

Prognostic Value of β-catenin Expression in Breast Cancer Patients: a Meta-analysis

(2015) De-Pu Zhang et al.   Asian Pacific Journal of Cancer Prevention

Role of epithelial–mesenchymal transition markers in triple-negative breast cancer

(2015) Sai Yin Cheung et al.   BREAST CANCER RESEARCH AND TREATMENT

Expression of epithelial-mesenchymal transition–related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome

(2015) Min Hye Jang et al.   HUMAN PATHOLOGY

Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients

(2015) Giuseppina Rosaria Rita Ricciardi et al.   PLoS One

Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression

(2014) Gilda Schmidt et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

(2014) Nadia Howlader et al.   JNCI-Journal of the National Cancer Institute

Downregulation of E-cadherin expression in breast cancer by promoter hypermethylation and its relation with progression and prognosis of tumor

(2014) Shohreh Alizadeh Shargh et al.   MEDICAL ONCOLOGY

Prognostic factors in patients with metastatic breast cancer at the time of diagnosis

(2014) Zhiyong Ren et al.   PATHOLOGY RESEARCH AND PRACTICE

The expression of β-catenin in different subtypes of breast cancer and its clinical significance

(2014) Shuguang Li et al.   TUMOR BIOLOGY

Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer

(2013) Hui Pang et al.   Cancer Epidemiology

Gene of the month: E-cadherin (CDH1)

(2013) Tamara M H Gall et al.   JOURNAL OF CLINICAL PATHOLOGY

Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients

(2013) Katarzyna Pogoda et al.   MEDICAL ONCOLOGY

A single-centre chart review exploring the adjusted association between breast cancer phenotype and prognosis

(2011) C. Hamm et al.   Current Oncology

The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer

(2011) Dabei Tang et al.   MEDICAL ONCOLOGY

Wnt/β-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome

(2010) Andrey I. Khramtsov et al.   AMERICAN JOURNAL OF PATHOLOGY

Significance of E-cadherin expression in triple-negative breast cancer

(2010) S Kashiwagi et al.   BRITISH JOURNAL OF CANCER

Cytoplasmic Localization of  -Catenin is a Marker of Poor Outcome in Breast Cancer Patients

(2010) E. Lopez-Knowles et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation

(2010) Felipe C Geyer et al.   MODERN PATHOLOGY

Molecular mechanisms controlling E-cadherin expression in breast cancer

(2009) Somesh Baranwal et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The Predictive Role of E-cadherin and Androgen Receptor on In Vitro Chemosensitivity in Triple-negative Breast Cancer

(2009) J. S. Koo et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

P-Cadherin and β-catenin are useful prognostic markers in breast cancer patients; β-catenin interacts with heat shock protein Hsp27

(2008) Mariel A. Fanelli et al.   CELL STRESS & CHAPERONES

Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype

(2007) B Mahler-Araujo et al.   JOURNAL OF CLINICAL PATHOLOGY